Min, Xiangzhen
Ma, Yan
Leng, Yufang
Li, Xiaoxi
Zhang, Jianmin
Xu, Shoucai
Wang, Xiuqin
Lv, Renjun
Guo, Jie
Xing, Huaixin
Funding for this research was provided by:
Beijing Medical Award Foundation (No YXJL-2023-0551-0143., No YXJL-2023-0551-0143., No YXJL-2023-0551-0143., No YXJL-2023-0551-0143., No YXJL-2023-0551-0143., No YXJL-2023-0551-0143., No YXJL-2023-0551-0143., No YXJL-2023-0551-0143., No YXJL-2023-0551-0143., No YXJL-2023-0551-0143.)
Article History
Received: 26 December 2023
Accepted: 5 April 2024
First Online: 8 May 2024
Declarations
:
: This study was approved by the Ethics Committee of the Cancer Hospital Affiliated with Shandong First Medical University before its start (SDTHEC2023003180). The trial was registered at the Chinese Clinical Trial Registry on 24/11/2023 (ChiCTR2300077948). All patients were informed of the research protocol and signed an informed consent form before enrolment.
: Not applicable.
: The authors declare no competing interests.